Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: Prognostication of short- and long-term outcomes

Bette J. Caan, Carol Sweeney, Laurel A. Habel, Marilyn L. Kwan, Candyce H. Kroenke, Erin K. Weltzien, Charles P. Quesenberry, Adrienne Castillo, Rachel E. Factor, Lawrence H. Kushi, Philip S. Bernard

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Background: The PAM50, a gene expression assay to categorize breast tumors into intrinsic subtypes, has not been previously used to examine short- and long-term prognostication in a population-based cohort where treatment patterns and time of initial follow-up vary. Methods: In a stratified case-cohort design of 1,691 women from the LACE and Pathways breast cancer survivor cohorts, we used PAM50 to categorize tumors into Luminal A (LumA), Luminal B (LumB), HER2- enriched (HER2-E), Basal-like and Normal-like, and to examine risk of early and late recurrence and mortality by Cox proportional hazards regression. Results: Compared withLumA, cumulative risk of recurrence and breast cancer death was higher for LumB, HER2-E, and Basal-like tumors at 2, 5, and 10 years. However, HR of breast cancer death varied over time [<5 years (early) vs. > 5 years (late)] for both Basal-like (HR, 6.23 early vs. HR, 0.63 late) and HER2-E tumors (HR, 2.97 early vs. HR, 0.73 late) but not for LumB tumors where risk was elevated consistently (HR, 2.67 early vs. HR, 1.47 late). The contrast between LumB, HER2-E, and Basal-like compared with LumA on early recurrence was stronger when subtype was defined by PAM50 than by immunohistochemistry (IHC) markers. Conclusions: The PAM50 categorized intrinsic subtypes in a manner that more accurately predicts recurrence and survival, especially for luminal tumors, compared with commonly used methods that rely on traditional IHC clinical markers. Impact: The PAM50 is robust for use in epidemiologic studies and should be considered when archived tumor tissues are available.

Original languageEnglish (US)
Pages (from-to)725-734
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: Prognostication of short- and long-term outcomes'. Together they form a unique fingerprint.

  • Cite this

    Caan, B. J., Sweeney, C., Habel, L. A., Kwan, M. L., Kroenke, C. H., Weltzien, E. K., Quesenberry, C. P., Castillo, A., Factor, R. E., Kushi, L. H., & Bernard, P. S. (2014). Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: Prognostication of short- and long-term outcomes. Cancer Epidemiology Biomarkers and Prevention, 23(5), 725-734. https://doi.org/10.1158/1055-9965.EPI-13-1017